Comparison of Commonly Used Diuretics
Full update May 2021
This chart reviews the indications, dosing, kinetics, cost, and place in therapy for commonly used diuretics.
NOTE: Information based on U.S. prescribing information unless otherwise noted. Indication and dosing information from Canadian labeling is provided if significantly different from U.S. labeling.
Diuretic/Availability |
USUAL Adult Dose Range |
Onset |
Duration |
Costa |
Comments |
THIAZIDE DIURETICS are among the drugs that significantly increase blood glucose. They can also increase cholesterol and triglycerides.1 Other side effects include hypokalemia, metabolic alkalosis, hyponatremia, and hypomagnesemia.1,6 Thiazides reduce renal calcium excretion, an effect that may be beneficial to people at risk of osteoporosis or kidney stones.1 |
|||||
Chlorothiazide (oral) Diuril |
Edema HTN |
≤2 hrs |
6 to 12 hrs |
500 mg: $2.91 |
N/A |
Chlorothiazide (IV) Sodium Diuril |
Edema |
15 min |
N/A |
500 mg injection: ~$120 |
|
Chlorthalidone 25, 50 mg tabs (U.S.); |
Edema HTN |
~2 hrs5 |
At least 24 hrs5 |
U.S.: Canada: |
|
Hydrochlorothiazide 12.5, 25 mg, 50 mg tabs; 12.5 mg cap (U.S.) |
Edema HTN |
2 hr |
6 to 12 hrs5 |
U.S.: Canada: |
|
Indapamide 1.25, 2.5 mg tabs |
Edema (U.S. only) HTN |
1 to 2 hrs6 |
At least 24 hrs6 |
U.S: Canada: |
|
Metolazone U.S.: 2.5, 5, 10 mg tabs Canada: 2.5 mg tabs |
Edema HTN |
≤1 hr |
≥24 hr (dose-dependent) |
U.S.: Canada (brand): |
|
LOOP DIURETICS are more potent diuretics than thiazides, but are less effective antihypertensives in most patients.1 They are best reserved for edematous conditions (e.g., heart failure, renal failure).1 Loops are recommended over thiazides for patients with GFR <30 mL/min/1.73 m2.1,7 A thiazide can be added to a loop to enhance diuresis.7 Like thiazides, loops can cause hypokalemia, metabolic alkalosis, and hypomagnesemia.1,8 Loops are less likely to cause hyponatremia.8 Loops increase excretion of calcium, instead of reducing it like thiazides.1 Loops can cause ototoxicity, usually with high IV doses in conjunction with other ototoxic medications.4 For edematous states, loops are usually dosed intermittently, as needed. For other tips on use, see our chart, Loop Diuretic Use in Heart Failure. |
|||||
Bumetanide (oral) U.S.: 0.5, 1, 2 mg tabs |
Edema: 0.5 to 2 mg QD. If needed, repeat every 4 to 5 hrs |
0.5 to 1 hr |
4 to 6 hrs (dose-dependent) |
U.S.: Canada (brand): |
|
Bumetanide (IV or IM) 0.25 mg/mL injection |
Edema |
IV: minutes IM: 40 min.5 |
3 to 6 hrs5 |
1 mg injection: ~$0.60 |
N/A |
Ethacrynic acid (oral) 25 mg tab |
Edema Take after a meal. |
30 min |
6 to 8 hr |
U.S.: Canada (brand): |
|
Ethacrynate sodium (IV) 50 mg injection |
Edema |
5 min |
2 hrs5 |
U.S. $~2,500 Canada: $135 |
|
Furosemide (oral) 20, 40, 80 mg tabs; 10 mg/mL oral solution; Lasix Special*(Canada) *see comments section |
Edema HTN |
<1 hr |
6 to 8 hr |
U.S.: 40 mg tab: <$0.10 Canada:40 mg tab: $0.04 |
|
Furosemide (IV or IM) 10 mg/mL injection |
Edema |
IV: 5 min |
IV: 2 hr |
U.S.: 20 mg/2 mL vial: ~$2.15 Canada: |
|
Torsemide (not available in Canada) 5, 10, 20 mg tabs |
Edema HTN |
1 hr5 |
12 to 16 hrs9 |
10 mg tab: ~$0.33 |
|
POTASSIUM-SPARING DIURETICS are usually weak antihypertensives, but they can be added to a thiazide to treat hypokalemia.1 They can increase the risk for hyperkalemia and should be used cautiously in patients with reduced kidney function and in those using an ACE inhibitor or ARB.4 |
|||||
Amiloride 5 mg tab |
5 to 20 mg QD See comments for indications. |
2 hr |
~24 hrs |
U.S.: 5 mg tab: $0.93 Canada (brand): 5 mg tab: $0.34 |
|
Eplerenone 25, 50 mg tabs |
HFrEF post-MI HTN Note: HFrEF indication requires dose reduction if potassium level ≥5.5 mEq/mL. Max dose 25 mg QD (HF) or BID (HTN) with moderate CYP3A4 inhibitors. |
Not available |
Not available |
U.S.: 50 mg tab: ~$2 Canada (brand): 50 mg tab: $3.08 |
|
Spironolactone 25, 50 (U.S. only), 100 mg tabs |
Edema HTN HF Hypokalemia (Canada) Primary hyperaldosteronism |
Not available |
2 to 3 days5 |
U.S.: 50 mg tab: ~$0.36 Canada: 25 mg tab: $0.09 |
100 to 400 mg/day pre-op (Canada: 75 to 400 mg/day), or lowest effective dose for maintenance.
400 mg/day x 4 days (short test), or 3 to 4 weeks (long test) |
Triamterene 50, 100 mg cap (Only combo products available in Canada.) |
Edema Take after meals. |
2 to 4 hr |
7 to 9 hr |
U.S. (brand): 50 mg cap: ~$9 |
|
Product labeling used in above chart, unless otherwise noted: U.S.: Diuril suspension (June 2020), Sodium Diuril injection (June 2018), chlorthalidone (Ascend, January 2021), hydrochlorothiazide tab (Accord, April 2020), hydrochlorothiazide cap (Aurobindo, September 2020), indapamide (ANI, April 2021), metolazone (Alembic, August 2020), Bumex tablets (August 2018), bumetanide injection (Hospira, November 2020), Edecrin (August 2020), Lasix (August 2018), furosemide oral solution (Morton Grove, September 2018), furosemide injection (Sagent, January 2021), amiloride (Par, November 2016), Inspra (August 2020), Aldactone (February 2021), Dyrenium (September 2019); Canada: chlorthalidone (AA Pharma, June 2010), Apo-hydrochlorothiazide (October 2020), Lozide (June 2020), Zaroxolyn (December 2018), Burinex (February 2021), Edecrin (December 2020), Lasix Special (February 2018), Lasix oral solution (February 2018), Teva-furosemide tablets (March 2020), furosemide injection (Sterimax, February 2017), Midamor (August 2010), Inspra (May 2020), Aldactone (July 2015)
Abbreviations: BID = twice daily; CrCl = creatinine clearance; GFR = glomerular filtration rate; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HTN = hypertension; IM = intramuscular; IV = intravenous; PO = oral; QD = once daily; RAS = renin-aldosterone system; TID = three times daily
- Wholesale acquisition cost (U.S.) per month (unless otherwise specified), for generic if available, of dose specified. U.S. medication pricing by Elsevier, accessed April 2021. Canadian cost is wholesale.
References
- Cheng JW. Essential hypertension. In: Zeind CS, Carvalho MG, editors. Koda-Kimble & Young’s Applied Therapeutics: the Clinical Use of Drugs. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2018:132-61.
- Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98.
- Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009;361:2153-64.
- Kumra R, Bargman JM. A review of diuretic use in dialysis patients. Adv Perit Dial 2014;30:115-9.
- Clinical Pharmacology powered by Clinical Key. Tampa, FL: Elsevier; 2021. http://www.clinicalkey.com. (Accessed April 7, 2021).
- e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2021. Thiazide CPhA monograph [May 2019]. http://www.e-therapeutics.ca. (Accessed April 7, 2021).
- Singh H, Marrs JC. Heart failure. In: Zeind CS, Carvalho MG, editors. Koda-Kimble & Young’s Applied Therapeutics: the Clinical Use of Drugs. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2018:261-305.
- Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens 2011;13:639-43.
- Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-e319.
- Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018;71:201-30.
- Jackson EK. Drugs affecting renal excretory function. In: Brunton LL, Hilal-Dandan R, Knollmann BC, Eds. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw-Hill, 2017: 445-70.
- Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol 2017;33:1342-433.
- Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:137-55.
- Sica DA. Eplerenone: a new aldosterone receptor antagonist - are the FDA’s restrictions appropriate? J Clin Hypertens 2002;4:441-5.
- Hripcsak G, Suchard MA, Shea S, et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020;180:542-51.
- Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8.
- Roush GC, Ernst ME, Kostis JB, et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015;65:1041-6.
- U.S. Department of Veterans Affairs. VA CSP Study No. 597: Diuretic Comparison Project https://www.research.va.gov/programs/csp/597/default.cfm. (Accessed April 19, 2021).
Cite this document as follows: Clinical Resource,Comparison of Commonly Used Diuretics. Pharmacist’s Letter/Prescriber’s Letter. May 2021. [370507]
Related Articles
- Answer Common Questions About First-Line BP Meds
- Guide Fluid De-Resuscitation in the ICU
- Don’t Consider a Specific Thiazide the “Clear Winner” for Hypertension
- you'll see more interest in using chlorthalidone instead of hydrochlorothiazide for hypertension
- whether hydrochlorothiazide should be used first-line for hypertension